Brief Summary
A Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomycomplete or partial removal of the prostate gland in Men with Newly Diagnosed Prostate Cancer (ASCERTAIN).
Intervention / Treatment
- Drug: Saruparib (AZD5305)
- Drug: Darolutamide
- Other: No Treatment
Inclusion Criteria:
- male participants >/= 18 years old
- participants deemed suitable for radical prostatectomy
- participants with localised prostate cancer with unfavourable intermediate/high/very high risk eligible for prostatectomy
- adequate organ and marrow function as per protocol
- capable of giving signed informed consent
- For participants participating in the Optional Genetic Research Only: Provision of signed and dated written Optional Genetic Research Information
- Available FFPE diagnostic tumour biopsyremoval of a section of tissue to analyse for cancer cells samples
- Participants must use a condom (with spermicide) from screening to 6 months after screening and refrain from fathering a child or donating sperm.